{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04340596",
            "orgStudyIdInfo": {
                "id": "ACTG A5386"
            },
            "secondaryIdInfos": [
                {
                    "id": "38639",
                    "type": "REGISTRY",
                    "domain": "DAIDS-ES Registry Number"
                }
            ],
            "organization": {
                "fullName": "National Institute of Allergy and Infectious Diseases (NIAID)",
                "class": "NIH"
            },
            "briefTitle": "Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption",
            "officialTitle": "A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "safety-tolerability-and-efficacy-of-il-superagonist-n-with-and-without-combination-broadly-neutralizing-antibodies-to-induce-hiv-control-during-analytic-treatment-interruption"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-05-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-03-23",
            "studyFirstSubmitQcDate": "2020-04-08",
            "studyFirstPostDateStruct": {
                "date": "2020-04-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "National Institute of Allergy and Infectious Diseases (NIAID)",
                "class": "NIH"
            },
            "collaborators": [
                {
                    "name": "Rockefeller University",
                    "class": "OTHER"
                },
                {
                    "name": "ImmunityBio, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).",
            "detailedDescription": "This study will evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).\n\nParticipants will be screened for eligibility and undergo leukapheresis, and a subset will also undergo optional rectal biopsy and/or lymph node fine needle aspirations (FNAs) (Step 1).\n\nAfter pre-entry and determination of eligibility in Step 1, participants will be randomized before Step 2 entry to either the N-803 only arm (Arm A) or the N-803 with combination bNAbs arm (Arm B):\n\n* Arm A will receive a dose of N-803, 6 mcg/kg, subcutaneously 1 week after Step 2 entry and then every 3 weeks for a total of eight doses (during the first 22 weeks).\n* Arm B will receive the following (during the first 22 weeks):\n\n  * Combination bNAb at Step 2 entry with VRC07-523LS dosed at 20 mg/kg and 10-1074 dosed at 30 mg/kg, intravenously;\n  * A dose of N-803, 6 mcg/kg, subcutaneously 1 week after Step 2 entry and then every 3 weeks for a total of eight doses;\n  * A second dose of 10-1074 at week 9 of Step 2 dosed at 30 mg/kg, intravenously\n\nAfter completing randomized treatment (Step 2), participants will interrupt antiretroviral therapy (ART) (Step 3) and will be followed closely to monitor for indications for reinitiation of ART (Step 4).\n\nAfter Step 2 entry, most participants will be followed for approximately 100 weeks across the remaining three study steps (i.e., Steps 2, 3, and 4).\n\nStep 1 will last up to 90 days, Step 2 will last approximately 52 weeks (study intervention), Step 3 will last up to 24 weeks (ATI), and Step 4 will last 24 weeks (ART restart)."
        },
        "conditionsModule": {
            "conditions": [
                "HIV Infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 46,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A: N-803 only",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive N-803 6 mcg/kg 1 week after Step 2 entry and then every 3 weeks for a total of eight doses.",
                    "interventionNames": [
                        "Biological: N-803 (IL-15 Superagonist)"
                    ]
                },
                {
                    "label": "Arm B: N-803 in combination with 10-1074 and VRC07-523LS",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive N-803 in combination with 10-1074 and VRC07-523LS as follows:\n\n* At Step 2 entry:\n\n  * VRC07-523LS 20 mg/kg\n  * 10-1074 30 mg/kg\n* At Step 2, week 1: N-803 6 mcg/kg every 3 weeks for eight doses\n* At Step 2, week 9: 10-1074 30 mg/kg",
                    "interventionNames": [
                        "Biological: N-803 (IL-15 Superagonist)",
                        "Biological: VRC07-523LS",
                        "Biological: 10-1074"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "N-803 (IL-15 Superagonist)",
                    "description": "Administered by subcutaneous (SQ) injection",
                    "armGroupLabels": [
                        "Arm A: N-803 only",
                        "Arm B: N-803 in combination with 10-1074 and VRC07-523LS"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "VRC07-523LS",
                    "description": "Administered by intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Arm B: N-803 in combination with 10-1074 and VRC07-523LS"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "10-1074",
                    "description": "Administered by intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Arm B: N-803 in combination with 10-1074 and VRC07-523LS"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurrence of a Grade \u22653 adverse event (AE) that is at least possibly related to N-803, as judged by the Clinical Management Committee (CMC)",
                    "timeFrame": "Step 2 week 1 to week 52"
                },
                {
                    "measure": "Number of N-803 doses completed",
                    "description": "Eight doses of N-803 are scheduled at the distinct time points listed in Time Frame. At each timepoint, dose completion status is recorded. Number of N-803 doses completed is the total number completed doses across all 8 timepoints.",
                    "timeFrame": "From step 2 week 1 to step 2 week 22"
                },
                {
                    "measure": "Proportion of participants requiring dose reduction",
                    "description": "Eight doses of N-803 are scheduled at distinct time points (Step 2 weeks 1, 4, 7, 10, 13, 16, 19 and 22). Proportion of participants requiring dose reduction is calculated as the number of participants who receive a reduced dose of N-803 at any of the 7 scheduled doses occurring after the first dose, divided by the total number of participants receiving N-803.",
                    "timeFrame": "From step 2 week 4 to step 2 week 22"
                },
                {
                    "measure": "Proportion of participants with plasma HIV-1 RNA <200 copies/mL 8 weeks after interruption of ART",
                    "timeFrame": "At step 3 week 8"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Occurrence of a Grade \u22652 AE without regard to relationship to study treatment",
                    "timeFrame": "Study entry to participant's last study visit, at approx. study week 100"
                },
                {
                    "measure": "Occurrence of a Grade \u22652 AE that is at least possibly related to N-803, as judged by the CMC",
                    "timeFrame": "Step 2 week 1 to week 52"
                },
                {
                    "measure": "Occurrence of a Grade \u22652 AE that is at least possibly related to VRC07-523LS or 10-1074",
                    "timeFrame": "Step 2 week 0 to week 52"
                },
                {
                    "measure": "Cell-associated HIV-1 RNA",
                    "timeFrame": "At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32"
                },
                {
                    "measure": "Measurement of HIV-1 reservoir (dQVOA)",
                    "timeFrame": "At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32"
                },
                {
                    "measure": "Measurement of plasma viremia by HIV-1 single copy assay",
                    "timeFrame": "At step 1 pre-entry evaluation and step 2 weeks 0, 1, 7, 13, 22 and 32"
                },
                {
                    "measure": "Measurement of intact proviral DNA",
                    "timeFrame": "At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32"
                },
                {
                    "measure": "Total HIV-1 DNA",
                    "timeFrame": "At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32"
                },
                {
                    "measure": "Proportion of participants with plasma HIV-1 RNA <200 copies/mL at 4, 12 and 24 weeks after interruption of ART in Step 3",
                    "timeFrame": "At step 3 weeks 4, 12, and 24"
                },
                {
                    "measure": "PK parameters: AUC0-\u03c4 of 10-1074",
                    "timeFrame": "At step 2 weeks 0, 1, 4, 7, 9, 10, 13, 16, 19, 22, 26, 32 and 46"
                },
                {
                    "measure": "PK parameters: AUC0-\u03c4 of VRC07-523LS",
                    "timeFrame": "At step 2 weeks 0, 1, 4, 7, 9, 10, 13, 16, 19, 22, 26, 32 and 46"
                },
                {
                    "measure": "Proportion of participants with antidrug antibodies",
                    "description": "Presence of anti-N803, anti-10-1074, and anti-VRC07-523LS antibodies",
                    "timeFrame": "At step 2 weeks 0, 1, 4, 7, 9, 10, 13, 16, 19, 22, 26, 32 and 46"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* HIV-1 infection\n* On ART for at least 96 weeks prior to randomization\n* On ART regimen containing an integrase inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIs) or dolutegravir/lamivudine for at least 6 weeks prior to randomization.\n* CD4 cell count \\>450 cells/mm\\^3 within 90 days prior to randomization\n* CD4 cell count nadir \u2265200 cells/mm\\^3.\n* Plasma HIV-1 RNA levels of \\<50 copies/mL for at least 96 weeks prior to randomization\n* Select laboratory results within 90 days of randomization\n* IC90 to 10-1074 of \u22641.5 mcg/mL, 10-1074 maximum percent inhibition (MPI) \u226598%, and IC80 to VRC07-523LS of \u22641 mcg/mL on the Monogram PhenoSense assay.\n* QTcF interval \u2264440 msec within 90 days prior to randomization.\n* For cisgender women and transgender men of reproductive potential, negative urine or serum pregnancy test within 30 days prior to randomization\n* Cisgender women and transgender men of reproductive potential must agree to use two methods of contraception, if participating in sexual activity that could lead to pregnancy.\n* Cisgender men and transgender women participants engaging in sexual activity that could lead to pregnancy and who are of reproductive potential must agree to use a barrier method of contraception\n* Willingness to abstain from sexual intercourse or use a barrier method of contraception consistently\n* Willingness to participate in an ATI.\n* Weight \\>50 kg and \\<115 kg.\n* Completion of pre-entry leukapheresis\n\nExclusion Criteria\n\n* History of AIDS-defining illness, with the exception of recurrent pneumonia.\n* History of or current clinical cardiovascular disease\n* Current clinically significant acute or chronic medical condition\n* History of HIV-associated neurocognitive disease\n* History of an HIV-associated malignancy\n* ART initiated during acute HIV infection\n* Current receipt of ART other than NRTI and integrase inhibitor.\n* Resistance to one or more drugs in two or more ARV drug classes.\n* Receipt of any therapeutic HIV vaccine or monoclonal antibody therapy (anti-HIV or otherwise) at any time in the past.\n* History of prior immunoglobulin (IgG) therapy.\n* History of use of any immunomodulatory medications within 6 months prior to randomization\n* Participation in another clinical study of an investigational product currently or within past 12 weeks\n* Breastfeeding or pregnancy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Timothy Wilkin, MD, MPH",
                    "affiliation": "Weill Medical College of Cornell University",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Alabama CRS (Site ID# 31788)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35222",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Logan, A.N.P.",
                            "role": "CONTACT",
                            "phone": "205-873-8686",
                            "email": "heatherlogan@uabmc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "UCLA CARE Center CRS",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90035",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aleen Khodabakhshian",
                            "role": "CONTACT",
                            "phone": "310-557-2273",
                            "phoneExt": "20891",
                            "email": "akhodabakhshian@mednet.ucla.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "UCSD Antiviral Research Center CRS (Site ID: 701)",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Steven Hendrickx, R.N.",
                            "role": "CONTACT",
                            "phone": "619-543-6968",
                            "email": "smhendrickx@health.ucsd.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Ucsf Hiv/Aids Crs",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elvira Gomez",
                            "role": "CONTACT",
                            "phone": "415-476-4082",
                            "phoneExt": "106",
                            "email": "elvira.gomez@ucsf.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Whitman-Walker Institute, Inc. CRS (Site ID: 31791)",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20005",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Avery A Wimpelberg, B.A., CCRC",
                            "role": "CONTACT",
                            "phone": "202-797-3589",
                            "email": "awimpelberg@whitman-walker.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Northwestern University CRS",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Baiba Berzins, M.P.H.",
                            "role": "CONTACT",
                            "phone": "312-695-5012",
                            "email": "Baiba@northwestern.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amy Sbrolla, R.N., B.S.N., A.C.R.N.",
                            "role": "CONTACT",
                            "phone": "1-617-7265598",
                            "email": "asbrolla@mgh.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Washington University Therapeutics (WT) CRS",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110-1010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael K Klebert",
                            "role": "CONTACT",
                            "phone": "314-747-1098",
                            "email": "mklebert@wustl.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "New Jersey Medical School Clinical Research Center CRS [Site ID: 31786]",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Newark",
                    "state": "New Jersey",
                    "zip": "07103",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christie L Costanza",
                            "role": "CONTACT",
                            "phone": "973-972-9069",
                            "email": "costancl@njms.rutgers.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.73566,
                        "lon": -74.17237
                    }
                },
                {
                    "facility": "Columbia P&S CRS",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Steven Palmer, PA-C",
                            "role": "CONTACT",
                            "phone": "212-342-2958",
                            "email": "sp500@cumc.columbia.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Weill Cornell Uptown CRS (Site ID: 7803)",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rebecca Fry, M.S.N., FNP",
                            "role": "CONTACT",
                            "phone": "212-746-4166",
                            "email": "ref2007@med.cornell.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Chapel Hill CRS (Site ID: 3201)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27599",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Becky Straub, B.S.N., M.P.H., R.N.",
                            "role": "CONTACT",
                            "phone": "1-919-843-9975",
                            "email": "bstraub@med.unc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Case Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jane Baum, R.N.",
                            "role": "CONTACT",
                            "phone": "216-844-2546",
                            "email": "baum.jane@clevelandactu.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Penn Therapeutics, CRS (Site ID: 6201)",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Baer, M.B., MBS",
                            "role": "CONTACT",
                            "phone": "215-349-5023",
                            "email": "Baer2@pennmedicine.upenn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "University of Pittsburgh CRS (Site ID# 1001)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stacey M. Edick, B.A., MPAS",
                            "role": "CONTACT",
                            "phone": "412-383-1748",
                            "email": "edicksm2@upmc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Individual participant data that underlie results in the publication, after deidentification.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.",
            "accessCriteria": "* With whom?\n\n  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.\n* For what types of analyses?\n\n  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.\n* By what mechanism will data be made available?\n\n  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group \"Data Request\" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015658",
                    "term": "HIV Infections"
                }
            ],
            "ancestors": [
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000015229",
                    "term": "Sexually Transmitted Diseases, Viral"
                },
                {
                    "id": "D000012749",
                    "term": "Sexually Transmitted Diseases"
                },
                {
                    "id": "D000016180",
                    "term": "Lentivirus Infections"
                },
                {
                    "id": "D000012192",
                    "term": "Retroviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "asFound": "HIV Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15558",
                    "name": "Sexually Transmitted Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17933",
                    "name": "Sexually Transmitted Diseases, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M18640",
                    "name": "Lentivirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15026",
                    "name": "Retroviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M21134",
                    "name": "Antibodies, Blocking",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}